Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Working Capital Changes (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Other Working Capital Changes for 11 consecutive years, with -$27.5 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 5746.81% to -$27.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.8 million through Dec 2025, down 1196.57% year-over-year, with the annual reading at -$28.8 million for FY2025, 1196.57% down from the prior year.
  • Other Working Capital Changes hit -$27.5 million in Q4 2025 for Voyager Therapeutics, down from $5.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $53.3 million in Q1 2022 to a low of -$27.5 million in Q4 2025.
  • Historically, Other Working Capital Changes has averaged $262500.0 across 5 years, with a median of -$444000.0 in 2023.
  • Biggest YoY gain for Other Working Capital Changes was 16616.1% in 2022; the steepest drop was 13030.26% in 2022.
  • Year by year, Other Working Capital Changes stood at -$152000.0 in 2021, then crashed by 13030.26% to -$20.0 million in 2022, then soared by 97.91% to -$418000.0 in 2023, then decreased by 12.44% to -$470000.0 in 2024, then crashed by 5746.81% to -$27.5 million in 2025.
  • Business Quant data shows Other Working Capital Changes for VYGR at -$27.5 million in Q4 2025, $5.9 million in Q3 2025, and -$6.4 million in Q2 2025.